SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Contact Us
Diabetes
Products
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Skip Navigation Links
Home
»
Investors
»
Press Releases
2019
2018
2017
2016
2015
2014
2013
Former Diamyd Medical
Data pager
Data pager
1
2
3
Show:
PageSizeComboBox
select
10
20
50
100
150
3 pages
Press Releases
Data pager
Data pager
1
2
3
Show:
PageSizeComboBox
select
10
20
50
100
150
3 pages
11-11-2019
Positive safety review of Remygen
®
gives clearance to start next part of Phase I/II trial in type 1 diabetes patients
10-17-2019
Diamyd Medical’s manufacturing process may be moved to a new manufacturer
10-15-2019
Diamyd Medical enters agreement for intralymphatic Diamyd
®
trial in LADA
10-2-2019
Year-End Report 18/19
9-17-2019
Preliminary results from GABA/Diamyd
®
trial
9-16-2019
Patients will be offered longer participation in the European Phase IIb trial with the diabetes vaccine Diamyd
®
9-9-2019
Feasibility study supports the use of intralymphatic injections of Diamyd
®
8-27-2019
Timeline update on GABA/Diamyd
®
and Remygen
®
clinical trials
6-26-2019
Quarterly Report III 18/19
6-18-2019
Diamyd Medical’s intralymphatic diabetes therapy attracts increased interest
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research